Teva Pharmaceuticals fails to prove that dose reduction for mifepristone when co-administered with a strong CYP3A inhibitor would have been obvious.
Method of Use Patents
December 27, 2021
PTAB rejects Examiner’s argument that crystalline form of an old compound would have been obvious based on obvious to try rationale.
Compound Patents
December 05, 2021